Therapeutic Perspectives in Atopic Dermatitis

Miséry, Laurent

doi:10.1007/s12016-010-8226-y

Cited by 28 publications

(11 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to Type I IFNs, IFN-γ does not get utilized as broadly in the clinic. However, IFN-γ has been shown to be effective in controlling sever idiopathic atopic dermatitis by decreasing blood eosinophil count, and inhibiting IgE synthesis and T-cell proliferation [69]. IFN-γ also has been used in patients with chronic granulomatous disease, a disorder with a defect in the enzyme complex responsible for phagocyte superoxide generation.…”

Section: Ifns As Therapeutic Agents In Other Diseasesmentioning

confidence: 99%

Interferons: Success in anti-viral immunotherapy

Lin¹,

Young²

2014

Cytokine & Growth Factor Reviews

231

172

View full text Add to dashboard Cite

The interferons (IFNs) are glycoproteins with strong antiviral activities that represent one of the first lines of host defense against invading pathogens. These proteins are classified into three groups, Type I, II and III IFNs, based on the structure of their receptors on the cell surface. Due to their ability to modulate immune responses, they have become attractive therapeutic options to control chronic virus infections. In combination with other drugs, Type I IFNs are considered a “standard of care” in suppressing Hepatitis C (HCV) and Hepatitis B (HBV) infections, while Type III IFN has generated encouraging results as a treatment for HCV infection in phase III clinical trials. However, though effective, using IFNs as a treatment is not without the need for caution. IFNs are such powerful cytokines that affect a wide array of cell types; as a result, patients usually experience unpleasant symptoms, with a percentage of patients suffering system wide effects. Thus, constant monitoring is required for patients treated with IFN in order to reach the treatment goals of suppressing virus infection and maintaining quality of life.

show abstract

Section: Ifns As Therapeutic Agents In Other Diseasesmentioning

confidence: 99%

Interferons: Success in anti-viral immunotherapy

Lin¹,

Young²

2014

Cytokine & Growth Factor Reviews

231

172

View full text Add to dashboard Cite

show abstract

“…The difficulties of treatment and the phobia toward topical steroids jeopardize patient care [6]. Research for new treatments is necessary [7]. The economic cost of disease management is high [8].…”

Section: Introductionmentioning

confidence: 99%

Nine-Year Follow-Up of Children with Atopic Dermatitis by General Practitioners

Miséry

Ansolabehere²,

Grandfils³

et al. 2014

Dermatology

Self Cite

View full text Add to dashboard Cite

The frequency of associated comorbidity and the cost of treatments in patients with atopic dermatitis (AD) followed up in primary care settings are poorly known. We carried out a retrospective cohort study on a longitudinal electronic medical records database of patients consulting a panel of general practitioners in France. All subjects with AD diagnosed during the first year of life were selected and matched with infants without the disease according to sex (1,163 vs. 1,163). Subjects were followed up for 9 years. Associated diseases, drug consumptions and available medical costs were detailed. Comparisons between subjects and controls were carried out. Subjects with AD had more comorbidities than others, especially in respiratory and ophthalmic system organs. The number of prescribed treatments in the field of skin diseases as well as overall medical costs (general practitioner consultations and prescribed drugs) were higher among atopic subjects, but differences were attenuated with age.

show abstract

“…(38) Practical approaches to treating atopic dermatitis currently include allergen-specific sublingual immunotherapy and therapy with anti-leukotriene drugs, probiotics, mycophenolate mofetil, leflunomide, intermittent fluticasone propionate ointment, topical anti-inflammatory substance, selective glucocorticoid receptor agonists, and inhibitors of IgE binding. (39,40) Accordingly, some promising anti-atopic agents are also expected to contain anti-inflammatory activity, since suppression of inflammation in the skin lesions is required for the treatment of atopic dermatitis. Rosmarinic acid, known to have anti-inflammatory activity, improved dryness, pruritus and general atopic dermatitis symptoms in clinical study.…”

Section: Discussionmentioning

confidence: 99%

Anti-inflammatory, antinociceptive and anti-angiogenic activities of a phospholipid mixture purified from porcine lung tissues

Jung¹,

Moon²,

Park³

et al. 2011

Immunopharmacology and Immunotoxicology

View full text Add to dashboard Cite

This work aimed to assess anti-inflammatory and related properties of a phospholipid mixture purified from porcine lung tissues, named KT&G101, which is being developed as a novel topical remedy for atopic dermatitis. KT&G101 consists of pure phospholipids, mainly phosphatidylcholine (PC) and other phospholipids such as phosphatidylinositol (PI) and phosphatidylserine (PS). Its predominant PC species is 1,2-dipalmitoylphosphatidylcholine (DPPC). KT&G101 exhibited an anti-angiogenic activity in the chick chorioallantoic membrane (CAM) assay. Oral administration of KT&G101 at the dosages of 100, 200 and 400 mg/kg body weight gave rise to an inhibition of 15.4%, 25.3% and 30.1% in the vascular permeability assay, respectively. In the carrageenan-induced inflammation in the air pouches, KT&G101 significantly diminished the volume of exudates in the pouches, the number of polymorphonuclear leukocytes and nitrite content in exudates. In the acetic acid-induced writhing response, oral administration of KT&G101 at the dosages of 50, 100 and 200 mg/kg body weight showed the reduction of 21.6%, 51.6% and 60.8% in the pain response of mice, respectively. It was also able to diminish the nitric oxide (NO) and reactive oxygen species (ROS) levels in the lipopolysaccharide (LPS)-stimulated RAW264.7 macrophage cells. KT&G101 displayed a significant suppression on the induction of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in the stimulated RAW264.7 cells. However, the free radical scavenging activity of KT&G101 was detected to be very weak in the 1,1-diphenyl-2-picrylhydrazyl (DPPH) assay. Taken together, KT&G101 possesses anti-inflammatory and related antinociceptive and anti-angiogenic activities, which indirectly supports its use as an anti-atopic therapy.

show abstract

Therapeutic Perspectives in Atopic Dermatitis

Cited by 28 publications

References 37 publications

Interferons: Success in anti-viral immunotherapy

Interferons: Success in anti-viral immunotherapy

Nine-Year Follow-Up of Children with Atopic Dermatitis by General Practitioners

Anti-inflammatory, antinociceptive and anti-angiogenic activities of a phospholipid mixture purified from porcine lung tissues

Contact Info

Product

Resources

About